Howe Li 李浩

Himalaya is a global clinical-stage biotechnology company with operations in San Diego, California, and Hong Kong, China. Himalaya is advancing its pipeline of novel monoclonal antibody and other protein therapeutic product candidates, which are designed to have more selective targeting, greater efficacy, and more cost-efficient and predictable manufacturing than traditional antibodies, through clinical trials. Its product candidates have been developed using CAB technology, which is protected by more than 500 issued and pending patents. Himalaya has two CAB programs currently in Phase 2 clinical testing in Hong Kong and Taiwan: BA3011, a novel conditionally active AXL-targeted antibody-drug conjugate (CAB-AXL-ADC), and BA3021, a novel conditionally active ROR2-targeted antibody-drug conjugate (CAB-ROR2-ADC). Himalaya has a co-development and collaboration agreement for an investigational CAB CTLA-4 antibody, BA3071, with BeiGene Ltd. for its development, manufacturing and commercialization in Greater China.

Teaching Clinical Development Section of Clinical Trial Protocol Design and GCP for Master Degree Prgram of "Executive Management and Transitional Medicine" (高级健康管理及转化医学硕士).

Clinical development, Drug safety and risk management, protocol design and clinical operation

DeltaMed is an innovative clinical iCRO focusing on providing regulatory affair, pharmacovigilance, medical monitoring, medical writing, and phase I services in China, DeltaMed is committed to providing one-stop efficient and high-quality pharmacovigilance, medical and Phase I clinical services with global standard and high regulatory compliance for local and global pharmaceutical and medical device companies. Currently we have offices in Shanghai, Hangzhou, Wuhan, Shenyang, Nanjing, Beijing, and San Diego, and have been providing services to over 100 clients with more than 300 projects. We also provide the integrated platform including CTMS, EDC, RTSM, eCTD, eTMF, ePRO with protocol specific workflows to enhance efficiency and high-quality of clinical operation. Please visit www.deltacro.com for more information about the company.

Tigermed-IntelliPV Co. Ltd is a subsidiary company of Tigermed Ltd,(www.tigermed.net) which is the largest CRO in China. Tigermed-IntelliPV Co. Ltd (TIPV) is a specialized Contract Research Organization (CRO) to provide Knowledge Process Outsourcing (KPO) services to pharmaceutical and healthcare companies. TIPV delivers global standard and comprehensive KPO services through a robust US/China business operation model in areas of pharmacovigilance/drug safety to global and local clients with cost-optimized solution. Our mission is to be a strategic partner for global pharmaceutical, life science as well as CRO companies to extend your resources and to offer high quality service with competitive cost saving. Our value is to provide a customer focused system of people, process and technology, working together to: 1) Improve Process Time Management; 2) Decrease Costs; 3) Maintain High Quality; 4) Ensure Regulatory Compliance; 5) Extend Flexible Resource; and 6) Build up a Solid Partnership. Tigermed-IntelliPV will provide the following services: 1. Comprehensive Case Management for English, Chinese, and Japanese case processing 2. Literature AE search (www.aelse.info) 3. Argus Safety Database Services 4. Signal Detection and Management 5. Postmarketing Study and Pharmacoepidemiology 6. Pharmacovigilance Consulting and Training 7. Safety Quality Assurance Services